- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Opinion
Video
Utility of Head-to-Head Studies in Psoriasis Management
Panelists discuss how head-to-head trials in psoriasis provide direct efficacy and safety comparisons between IL-17 inhibitors and other drug classes. Studies like BE RADIANT, BE VIVID, and IXORA-R highlight bimekizumab’s and ixekizumab’s superiority over secukinumab and ustekinumab. CLARITY and COBRA compare IL-17 to IL-23 inhibitors, while IMMerge and BE BOLD explore risankizumab’s role. These trials inform treatment decisions by guiding biologic selection based on efficacy, durability, and safety.
Video content above is prompted by the following:
There are several head-to-head studies of IL-17 inhibitors against other drug classes used in psoriasis as well as other IL-17 inhibitors. What head-to-head data have you found most compelling?
- BE RADIANT—bimekizumab vs secukinumab
- BE VIVID—bimekizumab vs ustekinumab
- CLARITY—secukinumab vs ustekinumab
- COBRA—brodalumab vs guselkumab
- IXORA-R—ixekizumab vs guselkumab
- IMMerge—risankizumab vs Secukinumab
- BE BOLD study of risankizumab vs bimekizumab in PsA announced (press release)
What is the clinical utility of head-to-head studies, and how do you use this data to navigate the psoriasis treatment landscape?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
